Algo news

Here is some news about Plus Therapeutics (PSTV):

1. **Consensus Rating and Short Interest Ratio**: Plus Therapeutics has a "Strong Buy" consensus rating, indicating positive sentiment among analysts. The short interest ratio for PSTV is over 15, suggesting that there is potential for a short squeeze, as high short interest can lead to a rapid increase in the stock price if significant numbers of shorted shares are covered.
Consensus Rating is Strong Buy; Short Interest Ratio > 15
|code|stock code|stock name|Last Price|Last Change|majority(Current Rating)|Interest Expenses (MRQ)|Latest Report Period|Latest Report End Date|Total Assets (MRQ)|Interest Expenses (MRQ) / Total Assets (MRQ)|market_code|
|---|---|---|---|---|---|---|---|---|---|---|---|
|PSTV|PSTV.O|Plus Therapeutics|0.319|-9.554862|Strong Buy|3759000|2025Q1|20250331|1.2056E7|0.31179495686794956|186|

In conclusion, Plus Therapeutics (PSTV) is a stock with strong buy consensus and high short interest ratio, which could indicate potential for a short squeeze.